The Impact of Targeted Temperature Management Duration on Thrombin Function in Cardiac Arrest Patients

Not Applicable

Not yet recruiting

• Conditions: Thrombin Function; Treatment Duration; Targeted Temperature Management; Cardiac Arrest

• Registration Number: NCT06543849
• Lead Sponsor: Tang Ziren

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-8-1
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Not yet recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Inclusion Criteria:<br><br> 1. age between 18 and 80 years;<br><br> 2. Glasgow Coma Scale score of less than 8 upon admission;<br><br> 3. patients resuscitated after out-of-hospital cardiac arrest; and (4) patient or their<br> legal representative has signed the informed consent form.<br><br>Exclusion Criteria:<br><br> 1. cardiac arrest caused by irreversible factors such as trauma or poisoning;<br><br> 2. cardiac arrest due to terminal conditions like advanced cancer;<br><br> 3. uncorrected persistent cardiogenic shock, defined as a systolic blood pressure below<br> 90 mmHg despite treatment with fluid resuscitation, vasopressors, and inotropic<br> agents;<br><br> 4. pre-existing cerebrovascular disease or CT-confirmed intracerebral hemorrhage upon<br> admission;<br><br> 5. pre-arrest Cerebral Performance Category (CPC) score between 3 and 5;<br><br> 6. bradycardia or sick sinus syndrome following the return of spontaneous circulation;<br><br> 7. pre-existing coagulation disorders or severe bleeding tendencies;<br><br> 8. pregnant or breastfeeding women, or women of childbearing age with elevated serum<br> hCG levels;<br><br> 9. presence of treatment limitations (such as refusal by the patient or legal<br> representative to undergo advanced life support, including mechanical ventilation,<br> chest compressions, or targeted temperature management);<br><br> 10. determination by the principal investigator that the patient is unsuitable for the<br> trial.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prothrombin Time (PT);Prothrombin Activity (PA);Activated Partial Thromboplastin Time (APTT);Thrombin Time (TT)

Secondary Outcome Measures

Name	Time	Method
The concentration of D-dimer (D-D);International Normalized Ratio (INR);The concentration of plasmin-a2-plasmin inhibitor complex (PIC);The concentration of fibrinogen (FBG);The concentration of thrombin-antithrombin complex (TAT);The concentration of thrombomodulin (TM);The concentration of tissue-type plasminogen activator inhibitor complex (T-PAIC);thrombelastogram (TEG);Platelet Count (PLT);The rate of bleeding-related events;The Milliliters of blood products;CPC Score